What question did this study set out to answer?

To design, synthesize, and evaluate new pyridopyrazinone derivatives as targeted inhibitors of mutated V600E BRAF kinase for anticancer therapy.

March 31, 2016European Journal of ChemistryOpen Access

Design, synthesis, anticancer evaluation and molecular docking of new V600EBRAF inhibitors derived from pyridopyrazinone

View Full Paper

Ask AI

Bookmark

Authors

KAKamelia M. AminCairo University OEOssama M. El-BadryAhram Canadian University DRDoaa E. Abdel RahmanCairo University

Discussion

Member takes

Implication

In vitro study reveals potent anticancer activity of novel pyridopyrazinone derivatives against V600E BRAF in cancer cell lines, highlighting their potential as targeted therapeutic agents.

Key Points

To design, synthesize, and evaluate new pyridopyrazinone derivatives as targeted inhibitors of mutated V600E BRAF kinase for anticancer therapy.
Synthesized novel pyridopyrazinone compounds modified at C-3 or fused with a triazine heterocycle at C-3 and C-4.
Evaluated in vitro cytotoxic efficacy against melanoma (LOXIMVI), ovarian (OVCAR3), thyroid (CAL62, FTC133, BCPAP, ML1), and colon (HT29, HCT116) cancer cell lines.
Conducted in vitro kinase assays against wild-type and V600E BRAF alongside molecular docking into the V600E BRAF active site.
Most synthesized derivatives showed anti-proliferative efficacy, with compound 3d displaying the strongest cytotoxic activity across all tested cancer cell lines.
Kinase inhibition assays identified compounds 1, 3d, 3e, 3h, 3i, 5d, 5e, and 6b as potent inhibitors of the V600E BRAF kinase enzyme.
Molecular docking verified strong binding interactions between the active derivatives and the kinase domain active site of V600E BRAF.

Cite This Study

Amin et al. (2016) studied this question.

synapsesocial.com/papers/6a72858fb27f158178280ffe https://doi.org/10.5155/eurjchem.7.1.19-29.1346

View Full Paper

Ask AI

Bookmark

Implication

In vitro study reveals potent anticancer activity of novel pyridopyrazinone derivatives against V600E BRAF in cancer cell lines, highlighting their potential as targeted therapeutic agents.

Design, synthesis, anticancer evaluation and molecular docking of new V600EBRAF inhibitors derived from pyridopyrazinone

Discussion

Member takes

Implication

Key Points

Cite This Study

Design, synthesis, anticancer evaluation and molecular docking of new V600EBRAF inhibitors derived from pyridopyrazinone

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider